BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoo D, Kim KM, Jin Y, Shim JH, Ko G, Yoon H, Sung K, Lee J, Kang Y, Lim Y, Lee HC, Chung Y, Lee YS, Suh DJ. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?: Efficacy of TACE in HCC with metastasis. Journal of Gastroenterology and Hepatology 2011;26:145-54. [DOI: 10.1111/j.1440-1746.2010.06341.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Li L, Gou C, Li J, Achakzai R, Li X. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C. Hepatobiliary & Pancreatic Diseases International 2016;15:152-7. [DOI: 10.1016/s1499-3872(16)60070-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zhang Y, Fan W, Wang Y, Huang G, Li J. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. Cancer Control. 2019;26:1073274819872216. [PMID: 31466465 DOI: 10.1177/1073274819872216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
3 Sato Y, Nishiofuku H, Yasumoto T, Nakatsuka A, Matsuo K, Kodama Y, Okubo H, Abo D, Takaki H, Inaba Y, Yamakado K. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. J Vasc Interv Radiol 2018;29:1061-7. [PMID: 29934260 DOI: 10.1016/j.jvir.2018.03.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
4 Tajiri K, Futsukaichi Y, Kobayashi S, Nagata K, Yasumura S, Takahara T, Minemura M, Yasuda I. Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2019;12:2205-14. [PMID: 30988625 DOI: 10.2147/OTT.S191741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang CL, Jiang FQ, Xu F, Jiang GX. ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma. Tumour Biol 2012;33:1535-41. [PMID: 22581584 DOI: 10.1007/s13277-012-0405-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kim JH, Shim JH, Yoon HK, Ko HK, Kim JW, Gwon DI. Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein. Liver Int 2018;38:1646-54. [PMID: 29436101 DOI: 10.1111/liv.13719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
7 Qu S, Zhang X, Wu Y, Meng Y, Pan H, Fang Q, Hu L, Zhang J, Wang R, Wei L, Wu D. Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Front Oncol 2022;12:874473. [DOI: 10.3389/fonc.2022.874473] [Reference Citation Analysis]
8 Li S, Wang Q, Mei J, Wang J, Zhong XP, Ling Y, Guo Z, Lu LH, Wei W, Guo R. Risk factors of extra-hepatic progression after transarterial chemoembolization for hepatocellular carcinoma patients: a retrospective study in 654 cases. J Cancer 2019;10:5007-14. [PMID: 31598173 DOI: 10.7150/jca.35355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Zou J, Zhu W, Meng H, Luo P, Zhang J. Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2019;13:271-9. [PMID: 30791765 DOI: 10.1080/17474124.2019.1570135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bauschke A, Altendorf-Hofmann A, Malessa C, Schüle S, Zanow J, Settmacher U. Which factors affect the long-term survival of patients with hepatocellular carcinoma UICC stage IV? J Cancer Res Clin Oncol 2016;142:2593-601. [PMID: 27630023 DOI: 10.1007/s00432-016-2260-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Ruiz-morales JM, Dorantes-heredia R, Chable-montero F, Vazquez-manjarrez S, Méndez-sánchez N, Motola-kuba D. Bone metastases as the initial presentation of hepatocellular carcinoma. Two case reports and a literature review. Annals of Hepatology 2014;13:838-42. [DOI: 10.1016/s1665-2681(19)30989-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
12 Patidar Y, Chandel K, Condati NK, Srinivasan SV, Mukund A, Sarin SK. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma – A Retrospective Study. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.12.009] [Reference Citation Analysis]
13 Huang YK, Yen CL, Shiu SI, Lee SW, Chang PY, Yeh HZ, Lee TY. Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma. PLoS One 2017;12:e0188999. [PMID: 29190692 DOI: 10.1371/journal.pone.0188999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu AL, Brunner TB. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol 2017;12:116. [PMID: 28701219 DOI: 10.1186/s13014-017-0851-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
15 Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol 2015; 21(36): 10327-10335 [PMID: 26420959 DOI: 10.3748/wjg.v21.i36.10327] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 50] [Article Influence: 7.7] [Reference Citation Analysis]
16 Hsieh YH, Hsieh SC, Lee CH, Yang SF, Cheng CW, Tang MJ, Lin CL, Lin CL, Chou RH. Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway. Oncotarget 2015;6:34859-74. [PMID: 26472188 DOI: 10.18632/oncotarget.5414] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
17 Kim KM. Nonsurgical multidisciplinary approach for recurrent hepatocellular carcinoma after surgical resection. Hepat Oncol 2015;2:29-38. [PMID: 30190985 DOI: 10.2217/hep.14.31] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Zhang Y, Huang G, Miao H, Song Z, Zhang X, Fan W, Wang Y, Li J, Chen Y. Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920937422. [PMID: 32754228 DOI: 10.1177/1758835920937422] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Qiu Z, Shen L, Jiang Y, Qiu J, Xu Z, Shi M, Yu Z, Ma Y, He W, Zheng Y, Li B, Wang G, Yuan Y. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Ann Transl Med 2021;9:283. [PMID: 33708910 DOI: 10.21037/atm-20-5360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N. A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. Cancer Biol Ther 2015;16:1453-61. [PMID: 26176896 DOI: 10.1080/15384047.2015.1070992] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
21 Lee JI, Kim JK, Kim DY, Ahn SH, Park JY, Kim SU, Kim BK, Han KH, Lee KS. Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. Clin Exp Metastasis. 2014;31:475-482. [PMID: 24496959 DOI: 10.1007/s10585-014-9641-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
22 Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma 2021;8:1565-77. [PMID: 34909425 DOI: 10.2147/JHC.S335879] [Reference Citation Analysis]
23 Garwood ER, Fidelman N, Hoch SE, Kerlan RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction: High-Risk Transarterial Chemoembolization Outcomes. Liver Transpl 2013;19:164-73. [DOI: 10.1002/lt.23552] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
24 Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, Liu QX, Luo JJ, Liu LX, Liu R, Qian S. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer. 2012;12:263. [PMID: 22721173 DOI: 10.1186/1471-2407-12-263] [Cited by in Crossref: 52] [Cited by in F6Publishing: 64] [Article Influence: 5.2] [Reference Citation Analysis]
25 Lee CH, Chang CJ, Lin YJ, Yen CL, Shen CH, Cheng YT, Lin CC, Hsieh SY. Nomogram predicting extrahepatic metastasis of hepatocellular carcinoma based on commonly available clinical data. JGH Open. 2019;3:38-45. [PMID: 30834339 DOI: 10.1002/jgh3.12102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
26 Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, Ryoo BY, Kang YK, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol. 2015;26:320-9.e6. [PMID: 25612807 DOI: 10.1016/j.jvir.2014.10.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
27 Chen D, Li Z, Song Q, Qian L, Xie B, Zhu J. Clinicopathological features and differential diagnosis of hepatocellular carcinoma in extrahepatic metastases. Medicine (Baltimore) 2018;97:e13356. [PMID: 30557986 DOI: 10.1097/MD.0000000000013356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
28 Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, Deng H, Li J, Shi M, Xu L, Guo R, Chen M, Wu P, Zhao M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. J Vasc Interv Radiol 2019;30:349-357.e2. [PMID: 30819477 DOI: 10.1016/j.jvir.2018.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
29 Zhao Y, Cai G, Zhou L, Liu L, Qi X, Bai M, Li Y, Fan D, Han G. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. Asia Pac J Clin Oncol. 2013;9:357-364. [PMID: 23714021 DOI: 10.1111/ajco.12081] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
30 Sartori Balbinot R, Facco Muscope AL, Dal Castel M, Sartori Balbinot S, Angelo Balbinot R, Soldera J. Intraparenchymal Hemorrhage due to Brain Metastasis of Hepatocellular Carcinoma. Case Rep Gastroenterol 2017;11:516-25. [PMID: 29033772 DOI: 10.1159/000479221] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Huang W, Chen Y, Chen L, Zhong J, Johri AM, Zhou J. Multimodality imaging-guided local injection of eccentric magnetic microcapsules with electromagnetically controlled drug release. Cancer Rep (Hoboken) 2019;2:e1154. [PMID: 32935461 DOI: 10.1002/cnr2.1154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
32 Conigliaro A, Costa V, Lo Dico A, Saieva L, Buccheri S, Dieli F, Manno M, Raccosta S, Mancone C, Tripodi M, De Leo G, Alessandro R. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer. 2015;14:155. [PMID: 26272696 DOI: 10.1186/s12943-015-0426-x] [Cited by in Crossref: 207] [Cited by in F6Publishing: 221] [Article Influence: 29.6] [Reference Citation Analysis]
33 Kim J, Sinn DH, Choi MS, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW. Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment? PLoS One 2019;14:e0213547. [PMID: 30845192 DOI: 10.1371/journal.pone.0213547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
34 Lee DW, Yim HJ, Seo YS, Na SK, Kim SY, Suh SJ, Hyun JJ, Jung SW, Jung YK, Koo JS, Kim JH, Yeon JE, Lee SW, Byun KS, Um SH. Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study. Liver Int. 2019;39:1109-1119. [PMID: 30972935 DOI: 10.1111/liv.14117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Lee S, Kim BK, Kim SU, Park Y, Chang S, Park JY, Kim do Y, Ahn SH, Chon CY, Han KH. Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS One. 2013;8:e77240. [PMID: 24155932 DOI: 10.1371/journal.pone.0077240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
36 Bukhari S, Ward K, Styler M. Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. Case Rep Oncol Med 2020;2020:8254236. [PMID: 33343953 DOI: 10.1155/2020/8254236] [Reference Citation Analysis]
37 Weintraub JL, Salem R. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. J Vasc Interv Radiol. 2013;24:1123-1134. [PMID: 23562168 DOI: 10.1016/j.jvir.2013.01.494] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
38 Xu L, Gao H, Huang J, Wang H, Zhou Z, Zhang Y, Li S, Chen M. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol 2015;30:1032-9. [PMID: 25639513 DOI: 10.1111/jgh.12910] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
39 Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W, Bakhtiar Ui Islam SM. Bone marrow metastasis presenting as bicytopenia originating from hepatocellular carcinoma. Clin Mol Hepatol 2016;22:267-71. [PMID: 27184470 DOI: 10.3350/cmh.2015.0017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
40 Aino H, Sumie S, Niizeki T, Kuromatsu R, Tajiri N, Nakano M, Satani M, Okamura S, Shimose S, Miyahara K, Torimura T. The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis. Mol Clin Oncol 2016;5:83-8. [PMID: 27330772 DOI: 10.3892/mco.2016.879] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
41 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
42 Koch C, Göller M, Schott E, Waidmann O, Op den Winkel M, Paprottka P, Zangos S, Vogl T, Bechstein WO, Zeuzem S, Kolligs FT, Trojan J. Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers. Cancers (Basel) 2021;13:2121. [PMID: 33924810 DOI: 10.3390/cancers13092121] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Kan X, Liang B, Zhou G, Xiong B, Pan F, Ren Y, Cao Y, Wang J, Yang F, Zheng C. Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol 2020;10:970. [PMID: 32733791 DOI: 10.3389/fonc.2020.00970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
44 Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263:590-599. [PMID: 22438359 DOI: 10.1148/radiol.12111550] [Cited by in Crossref: 126] [Cited by in F6Publishing: 131] [Article Influence: 12.6] [Reference Citation Analysis]
45 Wei K, Wang M, Zhang W, Mu H, Song TQ. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Med Oncol. 2014;31:969. [PMID: 24793745 DOI: 10.1007/s12032-014-0969-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
46 Yang X, Xu H, Zuo B, Yang X, Bian J, Long J, Wang D, Zhang J, Ning C, Wang Y, Xun Z, Wang Y, Lu X, Mao Y, Sang X, Zhao H. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. Hepatobiliary Surg Nutr 2021;10:434-42. [PMID: 34430522 DOI: 10.21037/hbsn-21-188] [Reference Citation Analysis]
47 Mupamombe C, Veluvolu R, Ahmad A, Preet M, Taiwo E. Advanced-stage hepatocellular carcinoma presenting without radiographic liver lesions. Clin Case Rep 2018;6:975-82. [PMID: 29881547 DOI: 10.1002/ccr3.1480] [Reference Citation Analysis]
48 Chen J, Zhou C, Long Y, Yin X. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. Tumour Biol 2015;36:183-91. [PMID: 25217986 DOI: 10.1007/s13277-014-2608-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
49 Yoo JJ, Lee JH, Lee SH, Lee M, Lee DH, Cho Y, Lee YB, Yu SJ, Kim HC, Kim YJ, Yoon JH, Kim CY, Lee HS. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases. PLoS One. 2014;9:e113926. [PMID: 25427152 DOI: 10.1371/journal.pone.0113926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
50 Lu SN. Cross-stage and combination treatment for Barcelona Clinic of Liver Cancer stage B (intermediate stage) hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:991-3. [PMID: 22621453 DOI: 10.1111/j.1440-1746.2012.07126.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Kim BH, Park JW. Systemic therapy for hepatocellular carcinoma: why do we keep failing? Hepat Oncol 2014;1:355-8. [PMID: 30190969 DOI: 10.2217/hep.14.23] [Reference Citation Analysis]
52 Kim HY, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 2014;3:9-17. [PMID: 24804173 DOI: 10.1159/000343854] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
53 Peng Z, Chen S, Wei M, Lin M, Jiang C, Mei J, Li B, Wang Y, Li J, Xie X, Chen M, Qian G, Kuang M. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. Radiology. 2018;287:705-714. [PMID: 29390197 DOI: 10.1148/radiol.2018171541] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
54 Lünse S, Döring P, Heidecke CD, Partecke LI. Giant hepatocellular carcinoma with bone metastasis in a young adult, emerged from pigmented adenoma with beta-Catenin activation: A case report. Int J Surg Case Rep 2017;36:18-21. [PMID: 28505585 DOI: 10.1016/j.ijscr.2017.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
55 Han Y, Cao G, Sun B, Wang J, Yan D, Xu H, Shi Q, Liu Z, Zhi W, Xu L, Liu B, Zou Y. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC Gastroenterol 2021;21:393. [PMID: 34670512 DOI: 10.1186/s12876-021-01967-3] [Reference Citation Analysis]
56 Yang Q, Zhang W, Liu Q, Liu L, Wu L, Wang J, Yan Z, Luo J. TACE Combined with Implantation of Irradiation Stent Versus TACE Combine with Bare Stent for HCC Complicated by IVCTT. Cardiovasc Intervent Radiol 2016;39:1280-8. [DOI: 10.1007/s00270-016-1372-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
57 Sayana H, Yousef O, Clarkston WK. Massive upper gastrointestinal hemorrhage due to invasive hepatocellular carcinoma and hepato-gastric fistula. World J Gastroenterol 2013; 19(42): 7472-7475 [PMID: 24259980 DOI: 10.3748/wjg.v19.i42.7472] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
58 Chung SW, Park MK, Cho YY, Park Y, Lee CH, Oh H, Jang H, Kim MA, Kim SW, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim HC, Kim YJ, Chung JW, Yoon JH, Lee JH. Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. J Hepatocell Carcinoma 2021;8:587-98. [PMID: 34164351 DOI: 10.2147/JHC.S294440] [Reference Citation Analysis]
59 Meng XC, Chen BH, Huang JJ, Huang WS, Cai MY, Zhou JW, Guo YJ, Zhu KS. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. World J Gastroenterol 2018; 24(4): 484-493 [PMID: 29398869 DOI: 10.3748/wjg.v24.i4.484] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
60 Chen C, Liu YQ, Qiu SX, Li Y, Yu NJ, Liu K, Zhong LM. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma. BMC Cancer 2021;21:693. [PMID: 34116652 DOI: 10.1186/s12885-021-08431-1] [Reference Citation Analysis]
61 Lee I, Huo T, Huang Y, Chao Y, Li C, Lee P, Chiang J, Su C, Lan K, Yang C, Wu J, Lin H, Lee S. Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatol Int 2012;6:753-62. [DOI: 10.1007/s12072-011-9322-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
62 Wei Q, Tian H, Luo H, Zhang Y, Deng Y, Yao J, Li H, Chen G, Yang Y. Better prognosis of hepatic resection combined with antiviral therapy for HBV-related hepatocellular carcinoma with BCLC Stage B/C. Asian Journal of Surgery 2017;40:453-62. [DOI: 10.1016/j.asjsur.2016.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
63 Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group). Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35:1036-1047. [PMID: 24750853 DOI: 10.1111/liv.12574] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
64 Yokoo T, Patel AD, Lev-Cohain N, Singal AG, Yopp AC, Pedrosa I. Extrahepatic metastasis risk of hepatocellular carcinoma based on α-fetoprotein and tumor staging parameters at cross-sectional imaging. Cancer Manag Res 2017;9:503-11. [PMID: 29081671 DOI: 10.2147/CMAR.S147097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
65 Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther. 2013;13:469-479. [PMID: 23560841 DOI: 10.1586/era.13.21] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
66 Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269:603-611. [PMID: 23864102 DOI: 10.1148/radiol.13130150] [Cited by in Crossref: 75] [Cited by in F6Publishing: 88] [Article Influence: 8.3] [Reference Citation Analysis]
67 Lee SW, Lee TY, Peng YC, Yang SS, Yeh HZ, Chang CS. The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma. J Dig Dis 2020;21:287-92. [PMID: 32315498 DOI: 10.1111/1751-2980.12866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
68 Li S, Mei J, Wang Q, Shi F, Liu H, Zhao M, Lu L, Ling Y, Guo Z, Guo Y, Chen X, Shi M, Lau WY, Wei W, Guo R. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice. Hepatobiliary Surg Nutr 2021;10:631-45. [PMID: 34760967 DOI: 10.21037/hbsn.2020.03.14] [Reference Citation Analysis]
69 Zhong BY, Ni CF, Yin GW, Chen L, Zhu HD, Guo JH, He SC, Deng G, Zhang Q, Li PC, Yu H, Teng GJ. Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2018;41:1867-76. [PMID: 30073478 DOI: 10.1007/s00270-018-2023-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol 2013; 5(7): 364-371 [PMID: 23898369 DOI: 10.4254/wjh.v5.i7.364] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
71 Hot S, Yeşiltaş M, Gökçek B, Eğin S, Şengiz S. Massive and life-threatening upper gastrointestinal bleeding due to invasive hepatocellular carcinoma: A case report. Int J Surg Case Rep 2016;26:69-72. [PMID: 27455113 DOI: 10.1016/j.ijscr.2016.06.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Chen S, Peng Z, Wei M, Liu W, Dai Z, Wang H, Mei J, Cheong M, Zhang H, Kuang M. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer 2018;18:392. [PMID: 29621988 DOI: 10.1186/s12885-018-4308-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
73 Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, Liu JS, Li HP, Bai W, Yin ZX, Fan DM, Zhang ZL, Han GH. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol. 2013;24:1786-1792. [PMID: 23508822 DOI: 10.1093/annonc/mdt072] [Cited by in Crossref: 72] [Cited by in F6Publishing: 78] [Article Influence: 8.0] [Reference Citation Analysis]
74 Chen X, Zhang HB, Li ZQ, Yu XF, Yang MF, Wang HH, Teng LS. Indocyanine green clearance in evaluating the recovery of liver reserve function after superselective transarterial chemoembolization. Hepatobiliary Pancreat Dis Int. 2013;12:656-660. [PMID: 24322753 DOI: 10.1016/s1499-3872(13)60103-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
75 Javan H, Dayyani F, Abi-Jaoudeh N. Therapy in Advanced Hepatocellular Carcinoma. Semin Intervent Radiol 2020;37:466-74. [PMID: 33328702 DOI: 10.1055/s-0040-1719187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
76 Woo HY, Rhee H, Yoo JE, Kim SH, Choi GH, Kim DY, Woo HG, Lee HS, Park YN. Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects. Liver Int 2021. [PMID: 34490997 DOI: 10.1111/liv.15051] [Reference Citation Analysis]
77 Nam HC, Sung PS, Song DS, Kwon JH, Nam SW, Yoon DJ, Jang JW, Choi JY, Yoon SK, Moon SW, Jang HS, Park JS, Jeun SS, Hong YK, Bae SH. Control of intracranial disease is associated with improved survival in patients with brain metastasis from hepatocellular carcinoma. Int J Clin Oncol. 2019;24:666-676. [PMID: 30788672 DOI: 10.1007/s10147-019-01407-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
78 Helal Tel A, Radwan NA, Shaker M. Extrahepatic metastases as initial manifestations of hepatocellular carcinoma: an Egyptian experience. Diagn Pathol 2015;10:82. [PMID: 26122043 DOI: 10.1186/s13000-015-0313-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
79 Aino H, Sumie S, Niizeki T, Kuromatsu R, Tajiri N, Nakano M, Satani M, Yamada S, Okamura S, Shimose S. Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis. Mol Clin Oncol. 2014;2:393-398. [PMID: 24772306 DOI: 10.3892/mco.2014.259] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
80 Lee HL, Tsai JT, Chen CY, Lin YC, Ho CB, Ting LL, Kuo CC, Lai IC, Lin CY, Tang JH, Huang YM, Kao WY, Cheng SW, Shen CN, Chen SW, Chiou JF. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. Ther Adv Med Oncol 2019;11:1758835919889002. [PMID: 31839809 DOI: 10.1177/1758835919889002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Agarwal A, Yadav AK, Kumar A, Gupta S, Panwala HK, Redhu N, Hariprasad S, Ranjan P, Arora A, Gupta A. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India. Indian J Gastroenterol 2015;34:117-26. [PMID: 25937484 DOI: 10.1007/s12664-015-0544-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
82 Xu MQ, Dai JJ, Jiang ZS, Xu F, Wang L, Zhang WJ, Guo ZG. Preoperative Combined Prediction Models Have Superior Capability in Predicting Survival as the Child-Pugh Grade in Patients with HCC after Interventional Embolotherapy. Cancer Manag Res 2020;12:12537-47. [PMID: 33324098 DOI: 10.2147/CMAR.S274970] [Reference Citation Analysis]
83 Mao K, Yan Y, Zhang J, Wang J, Wang R, Ling X, Liu Y, Lau WY, Jiang S, Liu J, Xiao Z. The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: A propensity score matching study. Cancer Med 2018;7:4475-84. [PMID: 30117307 DOI: 10.1002/cam4.1738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
84 Xu Y, Guo Q, Wei L. The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5096. [PMID: 34680245 DOI: 10.3390/cancers13205096] [Reference Citation Analysis]
85 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82. [PMID: 27508185 DOI: 10.2147/JHC.S50472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]